Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895127 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01895127 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 11 participants.
The verdict
NCT01895127, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.
Interventions
- DRUG Eculizumab
- BIOLOGICAL Immunoglobulin
- PROCEDURE Plasmapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895127
The ClinicalTrials.gov registry entry for NCT01895127 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Eculizumab is the first listed.
NCT01895127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01895127 about?
NCT01895127 is a clinical study titled "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation". This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.
What is the current status of trial NCT01895127?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2013-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01895127?
The interventions under investigation include: Eculizumab (DRUG), Immunoglobulin (BIOLOGICAL), Plasmapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT01895127?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.